Ontology highlight
ABSTRACT:
SUBMITTER: Hawley SA
PROVIDER: S-EPMC5689380 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
Hawley Simon A SA Ford Rebecca J RJ Smith Brennan K BK Gowans Graeme J GJ Mancini Sarah J SJ Pitt Ryan D RD Day Emily A EA Salt Ian P IP Steinberg Gregory R GR Hardie D Grahame DG
Diabetes 20160705 9
Canagliflozin, dapagliflozin, and empagliflozin, all recently approved for treatment of type 2 diabetes, were derived from the natural product phlorizin. They reduce hyperglycemia by inhibiting glucose reuptake by sodium/glucose cotransporter (SGLT) 2 in the kidney, without affecting intestinal glucose uptake by SGLT1. We now report that canagliflozin also activates AMPK, an effect also seen with phloretin (the aglycone breakdown product of phlorizin), but not to any significant extent with dapa ...[more]